Pay in 4 interest-free payments of $5.90 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Figure 1: FDA Approved Incretin Mimetic (GLP-1 and dual agonist) Diabetes and Obesity Products (as of December 2023) The Future of Incretin Mimetics in Diabetes and Obesity Looking Forward GLP-1 Clinical Development Pipeline Looking Forward GLP-1 Clinical Development Pipeline While Novo Nordisk and Eli Lilly dominate todays market, the success of incretin mimetics has attracted greater interest and investment, with a slew of potential new players aiming to enter and carve out their own space
(2022, 2023) illustrated that AVN-C protects C57BL/6 mice from SNHL induced by the anti-cancer drugs methotrexate and cisplatin
Previous drugs have been single- or dual-agonist drugs
Liraglutide is the second GLP-1RA to be approved after exenatide
Yet it also brings challenges in access, regulation, and trust
US$ 22.22
US$ 28.48
US$ 22.76
US$ 29.65
